At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 217 enrolled
Drug / intervention
Investigational mRNA-1273.815 +1 morebiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Randomized, Observer-Blind, Active-Controlled, Clinical Trial to Assess the Immunogenicity of an Investigational mRNA-1273.815 COVID-19 Vaccine in Previously Vaccinated Adults
In Brief
A Phase 3 clinical trial evaluating Investigational mRNA-1273.815 and Licensed Spikevax Vaccine for SARS-CoV-2. Completed, enrolled 217 participants across 7 sites.
Detailed Summary
To evaluate immune responses of an Investigational mRNA-1273.815 vaccine against the Omicron subvariant strain (XBB.1.5) of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsSARS-CoV-2
CountriesAustralia
Collaborators--
Timeline
Phase 3CompletedFinished
20252026
Enrollment StartApr 2024
First PostedApr 2024
Primary CompletionMay 2024
TodayJul 2026
First PostedApr 9, 2024
Enrollment StartApr 8, 2024
Primary CompletionMay 10, 2024
TodayJul 2, 2026
Enrollment to primary: 1 monthPosted 2.2 years ago
Interventions
Investigational mRNA-1273.815biological
Sterile solution for injection
Licensed Spikevax Vaccinebiological
Commercially available formulation